Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of 12.86 billion. The enterprise value is 9.92 billion.
| Market Cap | 12.86B |
| Enterprise Value | 9.92B |
Important Dates
The last earnings date was Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.94% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 62.86M |
Valuation Ratios
The trailing PE ratio is 11.81.
| PE Ratio | 11.81 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 4.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.04, with an EV/FCF ratio of 9.42.
| EV / Earnings | 9.11 |
| EV / Sales | 3.15 |
| EV / EBITDA | 9.04 |
| EV / EBIT | 9.57 |
| EV / FCF | 9.42 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.25 |
| Quick Ratio | 5.24 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.14 |
| Interest Coverage | 58.99 |
Financial Efficiency
Return on equity (ROE) is 22.97% and return on invested capital (ROIC) is 12.62%.
| Return on Equity (ROE) | 22.97% |
| Return on Assets (ROA) | 10.91% |
| Return on Invested Capital (ROIC) | 12.62% |
| Return on Capital Employed (ROCE) | 17.48% |
| Revenue Per Employee | 1.11M |
| Profits Per Employee | 406,011 |
| Employee Count | 2,682 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 16.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.73% in the last 52 weeks. The beta is 0.90, so Genmab's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -25.73% |
| 50-Day Moving Average | 211.70 |
| 200-Day Moving Average | 238.77 |
| Relative Strength Index (RSI) | 52.06 |
| Average Volume (20 Days) | 166 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of 2.99 billion and earned 1.09 billion in profits. Earnings per share was 16.85.
| Revenue | 2.99B |
| Gross Profit | 2.85B |
| Operating Income | 982.72M |
| Pretax Income | 1.27B |
| Net Income | 1.09B |
| EBITDA | 1.03B |
| EBIT | 982.72M |
| Earnings Per Share (EPS) | 16.85 |
Balance Sheet
The company has 2.93 billion in cash and 142.85 million in debt, giving a net cash position of 2.79 billion.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 142.85M |
| Net Cash | 2.79B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.09B |
| Book Value Per Share | 80.18 |
| Working Capital | 3.13B |
Cash Flow
In the last 12 months, operating cash flow was 1.08 billion and capital expenditures -25.96 million, giving a free cash flow of 1.05 billion.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -25.96M |
| Free Cash Flow | 1.05B |
| FCF Per Share | n/a |
Margins
Gross margin is 95.42%, with operating and profit margins of 32.89% and 36.44%.
| Gross Margin | 95.42% |
| Operating Margin | 32.89% |
| Pretax Margin | 42.57% |
| Profit Margin | 36.44% |
| EBITDA Margin | 34.33% |
| EBIT Margin | 32.89% |
| FCF Margin | 35.23% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.94% |
| Shareholder Yield | 1.94% |
| Earnings Yield | 8.47% |
| FCF Yield | 8.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 10.02.
| Altman Z-Score | 10.02 |
| Piotroski F-Score | n/a |